European Business Summits
info@ebsummit.eu – 0032 (0) 2 645 34 80
TRANSPARENCY REGISTER 268958411031-65
PRIVACY-POLICY | GENERAL TERMS OF SALES
European Health Summit
2022 EDITION
09:00
WELCOMING REMARKS
Arnaud Thysen
Director General
European Business Summits
09:20
HOW CAN THE EUROPEAN HEALTH DATA SPACE LEGISLATION BECOME THE ENABLER OF IMPROVED HEALTHCARE SERVICES?
Federico Milani
Deputy Head of the Unit “Data Policy and Innovation” DG CNECT, European Commission
Guillaume Byk
Legislative Officer DG SANTE, European Commission
Nicky Murphy
International Government Health Lead, Amazon Web Services (AWS)
Nicolas Monsarrat
Managing Director, Strategy & Consulting, Digital Health Lead, Accenture
Jack Parrock
EHS Moderator
If implemented, EHDS will become a game-changer for access to care for all European patients. But what needs to be done in order to make the data space work? Interoperability is key. Should existing health data infrastructures be leveraged to allow continuity and build on existing expertise? And how can strong investments for capacity building and training, particularly of smaller and non-profit organizations be ensured? Furthermore, assurance that alignment with all existing regulations, harmonization of interpretation and implementation of these regulations across the EU should be guaranteed.
10:20
INTERVIEW: HOW CAN WE REVITALISE THE ANTIBIOTIC PIPELINE?
In 2019, 4.95 million people died from illnesses in which antibiotic resistance played a part. Without effective prevention and treatment of infections, medical procedures such as organ transplantation, cancer chemotherapy, and major surgery will become too dangerous to perform. Despite the huge societal costs of AMR, there is currently no viable market for new antibiotics and pipelines are thin.
Mark Jones
Head of Development, Basilea Pharmaceutica
Amalie Holmgaard Mersh
Health Reporter, Euractiv
10:40
COFFEE BREAK
10:55
SHOWCASING THE POWER OF CROSS INDUSTRY COLLABORATION FOR DIGITAL ACCELERATION, INNOVATION AND GLOBAL HEALTH
Mati Gill
CEO, AION Lab
Dr. Nathalie Bloch
Chief BD, National Program of Bioconvergence- Israel Innovation Authority
Guy Spigelman
EMEA Lead, HCLS Startups, Amazon Web Services (AWS)
Kashif Sadiq
Founder & CEO, DenovAI Biotech
Yaron Shilat
Head of Public Policy Israel, Amazon Web Services (AWS)
Pharmaceutical innovation often occurs in silos, and startups entering the space sometimes struggle to identify and effectively address the most significant pain points within the industry. The launch of AION Labs has created partnerships where startups have access to the years of expertise and resources from pharma, and the technological innovation of AWS. The initiative is also supported by the Israeli government. We would like to run a panel session which would showcase the power of cross industry collaboration for digital acceleration, innovation and global health. As EU institutions discuss new pieces of legislation (such as the EHDS) and ways to enhance coordination on global health topics, we hope that this panel session will highlight the value of cross-industry collaboration and shine a light on technology innovation within healthcare.
11:45
WHY INVESTING IN THE INTEGRATION OF HEALTH AND THE ENVIRONMENT IS CRITICAL FOR PANDEMIC PREVENTION, PREPAREDNESS AND RESPONSE
Zakia Khattabi
Minister of Climate, Environment, Sustainable Development and Green Deal, Belgium
Prof. Christian Walzer
Executive Director of Health, Wildlife Conservation Society
Amalie Holmgaard Mersh
Health Reporter, Euractiv
The One Health approach recognizes the essential links between human, animal, and environmental health, and more fundamentally that biodiversity and intact ecosystems are foundational in maintaining the health of all, food systems and economies we all require. The COVID-19 pandemic, and other disease outbreaks of animal origin such as Ebola and Monkeypox, and their dramatic societal and economic costs highlight the urgency of applying a One Health approach across sectors and policies. Operationalizing the One Health approach is paramount in directing our future health in this acutely and irrevocably changed world. COVID-19 has shown us the exorbitant cost of inaction. The time to act is now.
12:15
NETWORKING LUNCH
13:00
INVESTING IN CARDIOVASCULAR HEALTH FOR HEALTHIER AND ECONOMICALLY STRONGER FUTURE
Prof. Robert Babela
State Secretary, Ministry of Health, Slovak Republic
Prof. Rifat Atun
Professor of Global Health Systems, Harvard University
Marie-France Tschudin
President, International & Chief Executive Officer, Novartis
Prof. Dennis Ostwald
CEO & Founder, WiFOR Institute
Hatice Kücük
Executive Director, G20 Health and Development Partnership
Cardiovascular Diseases is likely to be the largest healthcare crisis that healthcare system and a lot of governments will face in the next 20 years. This requires further mobilization of healthcare resources for improving delivery of care and access to care across countries. Evidence shows that investing in Health is associated with increase in the GDP contribution of the health economy across countries. Resources are always scarce, and it is important to prioritize investment in disease areas where return on investment will be highest. CVD in this stands out as a priority area and for best outcomes, any investment should be associated with an implementation plan that will result in the collaboration of all affected healthcare system stakeholders.
14:00
TOWARDS A RARE DISEASE MOONSHOT: SCALING UP PUBLIC PRIVATE PARTNERSHIPS TO ACCELERATE RESEARCH
Irene Norstedt
Director People Directorate, DG Research and Innovation, European Commission
Yann Le Cam
Chief Executive Officer, Eurordis
Claire Skentelbery
Director General, EuropaBio – the European Association for Bioindustries
Nathalie Moll
Director General, EFPIA
Anton Ussi
Operations & Finance Director, EATRIS ERIC
Mariam Zaidi
Euronews, Euractiv, NBC Presenter
95% of the 6,000-7,000 identified rare diseases don’t have an approved therapy. For most of these diseases, research is effectively non-existent. The search for new treatments is thwarted by enormous scientific challenges. At the current pace, it would take over 100 years to develop treatments for all rare conditions.
Public-private partnerships could help pool resources to solve problems more quickly, reduce fragmentation and scale up existing initiatives to make a real difference for patients. That’s why a coalition of partners is joining forces to accelerate research in rare and paediatric diseases and bring new therapies to patients.
15:00
BUILDING A SUSTAINABLE R&D ECOSYSTEM FOR RARE DISEASES
Dirk Vander Mijnsbrugge
Medical Lead Rare Diseases, International Developed Markets, Pfizer
Amanda Bok
CEO, European Haemophilia Consortium
Daria Julkowska
PhD, Assistant Director, Thematic Institute of Genetics, Genomics & Bioinformatics, INSERM, France
Andrew Thomson
Statistician, European Medicines Agency (EMA)
Mariam Zaidi
Euronews, Euractiv, NBC Presenter
Many rare and paediatric diseases suffer from limited understanding of disease pathophysiology, while the lack of potential drug targets precludes any investment. This is why there is a need for an open-science model aimed at making knowledge generated from scientific research transparent and accessible through shared collaborative networks. Through the combined knowledge of industry and academic experts we expect to identify and overcome a number of scientific/technical hurdles so that we can advance science for underserved rare diseases.
This panel will provide the opportunity for stakeholders – patients, academics, regulators and industry – to discuss how could stakeholders actively participate in this open-science model and what would the outcome of this model represent for them.
Public-private partnerships could help pool resources to solve problems more quickly, reduce fragmentation and scale up existing initiatives to make a real difference for patients. That’s why a coalition of partners is joining forces to accelerate research in rare and paediatric diseases and bring new therapies to patients.
16:00
COFFEE BREAK
16:15
PATIENTS ARE WAITING – WHAT MORE DO WE NEED TO DO TO ENSURE EUROPE IS A LEADER IN RARE DISEASE INNOVATION?
Radka Maxová
Member of the European Parliament
Tay Salimullah
Vice President, Global Head Value & Access, Novartis Gene Therapies
Alexander Natz
Secretary General, European Confederation of Pharmaceutical Entrepreneurs
Yann Le Cam
Chief Executive Officer, Eurordis
Elena Petelos
Vice President for HTA, EUPHA & Co-Chair for RWE & AI, HTAi
Giedrė Peseckytė
Health Reporter, Euractiv
30 million people live with rare diseases in Europe. Technological advances, particularly in the field of gene therapies, offer the promise of transforming the lives of patients and families. However, in many cases patients are still waiting to benefit. We will explore what is needed to enable Europe to be a world leader in rare disease research and innovation; and the importance of an EU Rare Disease Plan in supporting research and ultimately delivering effective treatments to patients.
17:15
HEALTHCARE ECONOMICS
Kristin Schreiber
Director for Chemicals, Health, Retail and Agrifood, DG GROW, European Commission
Brieuc Van Damme
CEO, King Baudouin Foundation
Heike Prinz
Executive Vice President, Head of Commercial Operations EMEA, Bayer
Roberto Servi
Vice President Global Marketing, Neuroscience Business Unit, Eli Lilly
Elizabeth Kuiper
Associate Director, European Policy Centre
Andy Bounds
EU Correspondent, Financial Times
Ensuring Europe`s competitiveness in health and fostering an economic resilience in a post pandemic world, strengthening resilience to vulnerabilities, gaps and areas of policy that need changing, harnessing technologies to produce dynamic economy. The panle will discuss what are the geopolitical implications for a stronger EU competitiveness in health and how to ensure healthcare innovation reaches patients?
18:10
EXCLUSIVE INTERVIEW
Margaritis Schinas
Vice President, EU Commissioner for Promoting our European Way of Life, European Commission
Andy Bounds
EU Correspondent, Financial Times
18:25
NETWORKING COCKTAIL
